GTX (GTXI) 2.95 -0.20

GTX, Inc.
(GTXI) 2.95 -0.20

Last Trade:	2.94	Day Range:	2.92 - 3.12
Trade Time:	04:05PM	52wk Range:	2.34 - 6.864
Prev. Close:	3.14	Market Cap:	184.65M
Open:	3.10	Div Yield:	0
Volume:	87387	PE:
EPS:	-0.71

The Latest On GTXI

GTx Surges as FDA Removes Clinical Hold 5/8/12 10:40am

GTx Announces Removal of Full Clinical Hold By FDA for Capesaris® In Advanced Prostate Cancer 5/8/12 6:39am

GTx Submits Clinical Hold Complete Response Letter To FDA For Its Planned Phase II Clinical Study Of Capesaris® For Secondary Hormonal Therapy of Advanced Prostate Cancer 4/4/12 6:37am

Morning Social Media Outlook for Tuesday Feb 21 (CHG, SKS, GTXI, CTRP) 2/21/12 12:45pm

Benzinga's Top Pre-Market Losers 2/21/12 9:20am

A Peek Into The Market Before The Trading Starts 2/21/12 8:28am

GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris for First and Second Line Treatments of Advanced Prostate Cancer 2/21/12 7:46am

Benzinga's Top Pre-Market Gainers 1/31/12 9:18am

Morning Market Movers 1/30/12 11:01am

Citi Raises Price Target on GTx to $19 1/30/12 9:39am

Benzinga's Top Pre-Market Gainers 1/30/12 9:14am

Investor Ideas' Tuesday's NASDAQ Winners 12/21/11 2:15pm

GTx Surges as FDA Removes Clinical Hold 5/8/12

GTx Announces Removal of Full Clinical Hold By FDA for Capesaris® In Advanced Prostate Cancer 5/8/12

GTx Submits Clinical Hold Complete Response Letter To FDA For Its Planned Phase II Clinical Study Of Capesaris® For Secondary Hormonal Therapy of Advanced Prostate Cancer 4/4/12

Morning Social Media Outlook for Tuesday Feb 21 (CHG, SKS, GTXI, CTRP) 2/21/12

Benzinga's Top Pre-Market Losers 2/21/12

A Peek Into The Market Before The Trading Starts 2/21/12

GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris for First and Second Line Treatments of Advanced Prostate Cancer 2/21/12

Benzinga's Top Pre-Market Gainers 1/31/12

Morning Market Movers 1/30/12

Citi Raises Price Target on GTx to $19 1/30/12

Benzinga's Top Pre-Market Gainers 1/30/12

Investor Ideas' Tuesday's NASDAQ Winners 12/21/11

Morning Social Media Outlook for Tuesday Feb 21 (CHG, SKS, GTXI, CTRP) 2/21/12

Biotech Leads Friday's NASDAQ Winners 10/17/11

Top Percentage Gainers and Losers as of 2pm 6/23/11 6/23/11

Top Percentage Gainers and Losers as of 12pm 6/23/11 6/23/11

Top Percentage Gainers and Losers as of 2pm 6/21/11 6/21/11

Top Percentage Gainers and Losers as of 12pm 6/21/11 6/21/11

Top Percentage Gainers and Losers as of 2pm 6/20/11 6/20/11

Top Percentage Gainers and Losers as of 2pm 5/02/11 (GENE, ICO, SCOK, DISH, OMN, TSTC, GXTI, ACI, MOBI, SIFY, PACB, DMD, TRGL, CELL, USAT) 5/2/11

Implied Vol Remains Elevated on GTXI Ahead of JPM Healthcare Conference 1/11/11

Market Roundup (MOT, LOJN, GTXI, AMLN, ILMN, FFIV) 10/27/10

Benzinga's Top Pre-Market NASDAQ Losers (GTXI, BWLD, CENX, PNRA) 10/27/10

Options Traders Bullish on GTx, Inc. (GTXI) 10/4/10

Citi Raises Price Target on GTx to $19 1/30/12

Rodman & Renshaw Maintains OUTPERFORM Rating on GTX, Inc. 11/7/11

Jefferies Maintains Buy Rating and $6 PT on GTX 10/20/11

Rodman & Renshaw Initiates GTXI at Market Outperform, $7 PT 10/14/11

Wedbush Initiates GTXI At Outperform, $13 PT 7/20/11

Citi Provides Color on GTx, Buy 6/6/11

Benzinga's Top Upgrades (GTXI, PRGO, RVBD, ITMN) 4/13/11

UPDATE: Citi Upgrades GTx Inc to Buy (GTXI) 4/13/11

Trade GTXI
NOW!

Partner Headlines

GTx Inc. Reports Operating Results (10-Q) 5/10/12

Weekly CEO Sells Highlight: GTX, Signet Group, Qlik Tech, Voxx 4/16/12

GTx Inc. (GTXI) CEO, 10% Owner Mitchell Shuster Steiner sells 27,722 Shares 4/12/12

GTx Inc. (GTXI) CEO, 10% Owner Mitchell Shuster Steiner sells 43,423 Shares 4/10/12

5 Stocks Insiders Love Right Now 3/15/12

Insider Buying at GTXI after Price Plunge (GTXI, ABT, MDT) 3/12/12

Insiders Trading AMAG, CLWR, GTXI 3/6/12

GTx Inc. Reports Operating Results (10-K) 3/2/12

GTx Inc. Reports Operating Results (10-Q) 11/4/11

5 Stocks With Big Insider Buying 7/1/11

Insiders Trading KIOR, NWN, GTXI 6/29/11

Press Releases

GTx Announces Webcast of Corporate Presentation at Jefferies 2012 Global Healthcare Conference 5/29/12 Business Wire

GTx Provides Corporate Update and Reports First Quarter 2012 Financial Results 5/8/12 Business Wire

GTx Announces Removal of Full Clinical Hold By FDA for Capesaris® In Advanced Prostate Cancer 5/8/12 Business Wire

GTx, Inc. To Host First Quarter 2012 Financial Results Conference Call and Webcast 4/25/12 Business Wire

GTx Submits Clinical Hold Complete Response Letter To FDA For Its Planned Phase II Clinical Study Of Capesaris® For Secondary Hormonal Therapy of Advanced Prostate Cancer 4/4/12 Business Wire

GTx Announces Webcast of Corporate Presentation at the Cowen and Co. Annual Health Care Conference 3/2/12 Business Wire

GTx Announces Webcast of Corporate Presentation at the Citi 2012 Global Health Care Conference 2/24/12 Business Wire

GTx Provides Corporate Update and Reports 2011 Financial Results 2/21/12 Business Wire

GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris® for First and Second Line Treatments of Advanced Prostate Cancer 2/21/12 Business Wire

GTx, Inc. To Host Fourth Quarter and Full Year 2011 Financial Results Conference Call and Webcast 2/13/12 Business Wire

Get the latest GTXI stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for GTX, Inc. stock price.

GTX, Inc. by YCharts

GTX (GTXI) 2.95 -0.20

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On GTXI

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social